Abstract
Clinical oncology has struggled for decades with the predicament of the toxicity of chemotherapy for the treatment of malignant disease. For example, cisplatin and its analogues, carboplatin and oxaliplatin, are commonly used anticancer agents, but they are particularly toxic. Moreover, some patients benefit substantially from treatment with these drugs, whereas others suffer the toxic effects of the drugs without obtaining real benefit. The use of molecular markers to help identify who may benefit and who may not is one of the most exciting new areas of study in oncology.The randomized International Adjuvant Lung Cancer Trial (IALT) found a modest . . .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
